About Aptus Endosystems
Aptus Endosystems is a medical device company focused on developing advanced technology for endovascular aneurysm repair (EVAR). Aptus Endosystems has developed an endograft and helical anchor technology that allows physicians to perform minimally invasive EVAR while still providing the control and potential long term durability of an open surgical repair. The Fortevo AAA Endograft System and the HeliFX Aortic Securement System bear the CE Mark for distribution in the European Union. The HeliFX Aortic Securement System is cleared by the FDA for distribution in the United States. The Fortevo AAA Endograft System is Investigational Use Only in the United States.
Missing: Aptus Endosystems's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Aptus Endosystems's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Aptus Endosystems
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Aptus Endosystems is included in 1 Expert Collection, including Medical Devices.
Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)
Aptus Endosystems Patents
Aptus Endosystems has filed 19 patents.
Implants (medicine), Prosthetics, Vascular diseases, Diseases of the aorta, Vascular surgery
Implants (medicine), Prosthetics, Vascular diseases, Diseases of the aorta, Vascular surgery
Latest Aptus Endosystems News
Nov 16, 2015
Medtronic Acquires Aptus Endosystems "Leveraging decades of clinical experiences and data, our core technologies for treating abdominal aortic aneurysm (AAA) and descending thoracic disease, Endurant® and Valiant® product lines, have been proven in more than 280,000 patients globally," said Daveen Chopra, vice president and general manager of the Aortic business, which is part of the Aortic & Peripheral Vascular division at Medtronic. "Our mission to improve patient outcomes drives our commitment to build on our success and invest in complementary innovative technology that will allow physicians to treat more complex aortic disease. " The VEITHsymposium will begin with a special session focusing on new developments in AAA and endovascular aneurysm repair (EVAR). This session will feature the highly anticipated four-year subset results on hostile neck anatomies from the ENGAGE Global Registry for Medtronic's Endurant AAA stent graft system. Verhagen, M.D., Ph.D., Professor and Chief of Vascular Surgery, Erasmus University Medical Center in Rotterdam, the Netherlands, will present this real-world data on the opening day of VEITH. Additionally, four-year results from the full ENGAGE registry cohort will be presented on Saturday, November 21, 2015, by Marc R.H.M van Sambeek, M.D., Ph.D, Department of Vascular Surgery, Catharina Hospital, Eindhoven, the Netherlands. Medtronic's recently acquired EndoAnchor system will also be highlighted in nine presentations examining clinical applicability. The Heli-FX® EndoAnchor® system is an endovascular deployed anchor designed to attach a variety of aortic endografts to the native vessel wall. Finally, several Medtronic products in clinical trials will be highlighted, such as the Endurant® Evo AAA stent graft system, as well as products for complex aortic disease, including: Modified Valiant devices used in the treatment of ascending arch disease. One-year results from the early feasibility of the Valiant "Mona LSA®" branch thoracic stent graft system. The initial experience in the treatment of thoracoabdominal with modified Medtronic stent grafts. Key Events: Tuesday, November 17 6:51 am - 6:56 am Redefining Adverse Neck Morphology With Newer EVAR Devices Which Perform Better In Short, Angulated, and Large Diameter Necks And Those With A Thrombus Burden: What Are the Limits?, from the ENGAGE Registry 7:20 am - 7:25 am Endograft Repair Of Ascending Aortic Lesions And Type A Dissections With A Physician Sponsored IDE (PSIDE) For A Modified Valiant Device: Lessons Learned And What Are The Prospects For An Endograft-Valve Combined Device? Noon - 1 pm Treating Challenging Anatomies in TEVAR and EVAR. New York Hilton Midtown, Gramercy West 2nd Floor, a Medtronic sponsored event Wednesday, November 18 9:05am - 9:09 am DEBATE: EVAR With Short Necks Are Best Treated With Standard EVAR Using Newer Endograft Devices Thursday, November 19 7:46am - 7:51am Newly Modified Medtronic Endurant (Evo) Endograft (investigational device): Initial Clinical Experience And Advantages 10:17am - 10:22am A New Manifold Branched Endograft Device (investigational device) For Treating TAAAs And Other Complex Aortic Lesions: Concept, Advantages, Initial Clinical Experience 11:26am - 11:31am The Medtronic Branched TEVAR Endograft, The Valiant Mona LSA System (investigational device): Technique, Advantages and Results 3:40pm - 4:47pm Session 61: Preventing And Treating Migration and Endoleaks: Update on Heli-Fx EndoAnchors Details such as times, titles and locations are subject to change. In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world. About VEITH symposium Now in its 42nd year, VEITHsymposium provides vascular surgeons, interventional radiologists, interventional cardiologists and other vascular specialists with a unique and exciting format to learn the most current information about what is new and important in the treatment of vascular disease. The 5-day event features rapid-fire presentations from world renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques. For more information, please visit www.VEITHpress.org or contact Pauline T. Mayer at 631.979.3780. About Medtronic Medtronic plc ( www.medtronic.com ), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 85,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together. Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results. -end-
Aptus Endosystems Frequently Asked Questions (FAQ)
When was Aptus Endosystems founded?
Aptus Endosystems was founded in 2002.
Where is Aptus Endosystems's headquarters?
Aptus Endosystems's headquarters is located at 271 Gibraltar Drive, Sunnyvale.
What is Aptus Endosystems's latest funding round?
Aptus Endosystems's latest funding round is Acquired.
How much did Aptus Endosystems raise?
Aptus Endosystems raised a total of $96M.
Who are the investors of Aptus Endosystems?
Investors of Aptus Endosystems include Medtronic, U.S. Venture Partners, Longitude Capital, Synergy Life Science Partners, Pequot Venture Capital and 7 more.
Who are Aptus Endosystems's competitors?
Competitors of Aptus Endosystems include Monteris Medical, Epitomee Medical, Endologix, Uromedica, Ecochlor, Calibra Medical, Triangle Biosystems, Nellix Endovascular, Micrus Endovascular, Satiety and 12 more.
Compare Aptus Endosystems to Competitors
Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.
Satiety, Inc. is a medical device company focused on the development of less invasive devices for the treatment of obesity. Obesity is a global health problem, affecting 70 million people in the U.S. and 300 million worldwide, and growth of which is causing increases in obesity-related diseases such as diabetes, high blood pressure and cardiovascular disease. Obesity surgery has been shown to be the only long-term effective means of weight loss for morbidly obese patients. Satiety's first product, the TOGA System, enables physicians to perform a procedure similar to traditional restrictive obesity surgeries, but without surgical incisions. In this procedure, the TOGA System devices are inserted transorally (through the mouth) and are used to reduce the capacity of the stomach to give patients a feeling of fullness after a small meal. The procedure is intended to be safer and easier for patients to tolerate than conventional obesity surgery. Safety and effectiveness of the TOGA System are currently being evaluated in a multi-center U.S. Study and the system is not available for sale in the United States.
Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.
Emphasys Medical has developed an innovative device called the Emphasys Endobronchial Valve* (EBV). The EBV is implanted in the diseased portions of the lung and utilizes a one-way valve to prevent air from entering the diseased lung segments during inhalation yet allows trapped air to vent during exhalation. This design is intended to allow inhaled air to be redirected to the healthier, functional parts of the lung. The Emphasys procedure is a minimally invasive treatment option in which the device is placed in selectively targeted areas of the affected lung determined by the extent of the emphysema damage.
DuoCure offers intraluminal minimally invasive implantable device for treatment of obesity.
NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. The company was founded in 2007 and is based in Minneapolis, Minnesota.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.